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Which are the Parameters to be Controlled in 
Red Cell Products (Whole Blood, Red Cell Concentrates, 
Washed Red Cells, Leucocyte Poor Red Cell Concentrates, 
Frozen Red Cells) in Order that They May be Offered to the 
Medical Profession as Standardised Products with 
Specified Properties? 
It has become an established practice to William L. Bayer, MD 
consider plasma derivatives as biologicals of 
human origin and to subject them to strict 
quality controls. There is an increasing - and 
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justified - tendency to apply the same prin- 
ciples to cellular blood components. Which 
are the parameters to be in red 
cell Products (whole blood, red cell concen- 
B. Genetet and P .  Mannoni. French law imposes 
only a few requirements to which whole blood or 
concentrated red cell suspensions used for trans- 
trates, washed red cells, leukocyte-poor red 
cell concentrates, frozen red cells) in order 
that the,, may be offered to the medical 
specified properties? 
fusion must conform. Apart from the need to screen 
blood for syphilis and hepatitis B virus and to en- 
sure immunologic donor-recipient compatibility, 
the only restriction imposed by law is that a mini- 
cipient's circlation 24 h post-transfusion, a crite- 
profession as products With mum of 70% injected cells be present in the re- 
William L. Bayer. The present technical stand- 
ards of the American Association of Blood Banks 
[l] and United States Bureau of Biologics [2] are 
in my opinion sufficient to meet the needs of the 
medical practice for red cell preparations adequate 
for the clinical purposes for which they are trans- 
fused. 
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rion of in vivo survival which takes little account 
of red cell oxygen carrying capacity. This relative 
freedom from legal impositions is, however, being 
somewhat eroded: a bill was passed on February 
20, 1980 [3] requiring blood banks to set up ac- 
curate protocols for the preparation of unstable 
components and for quality control procedures to  
be performed at each stage of their preparation. 
Quality control has thus become part of blood 
banking in France. To be effective it should assess 
three main factors: (1) functional adequacy: this is 
an area hitherto neglected to a certain extent and 
concerns oxygen transport and release and micro- 
circulation properties, namely red cell deformabil- 
ity ; (2) quantitative adequacy; this concerns the 
quantities of each blood product per unit of whole 
blood or packed red cells, and (3) transfusion haz- 
ards: this covers a number of areas, including im- 
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munology, bacteriology, virology and possibly toxi- 
cology. 
Tests are therefore needed to determine trans- 
fusion efficacy and ascertain the absence or virtual 
absence of risk. 
Briefly, blood quality is determined by: choice 
of donor; blood collection [6],  transfer and storage 
conditions; and technical stringency in the prep- 
aration of washed or frozen concentrated red cell 
suspensions, and leukocyte-poor and platelet-poor 
red cell suspensions. Much could be said about 
quality control in each of these five areas. Suffice 
it here simply to stress the need for such controls. 
It goes without saying that not all units need 
be submitted to control, but strict adherence to 
standard sampling techniques is, of course, a key 
element in good quality control. 
Functional Tests 
Estimations of intracellular red cell pyruvate 
kinase activity and glucose concentration are nec- 
essary for an overall assessment of the erythro- 
cyte metabolic potential on which the red cell’s 
functional properties depend. Red cell oxygen de- 
livery capacity must also be evaluated. Valtis and 
Kennedy [8] have shown that the oxygen unload- 
ing capacity of red cells is a function of the dura- 
tion of blood storage at 4 O C .  Other studies [l] 
have shown clearly that the oxygen delivery capac- 
ity of red cells also depends on the anticoagulant- 
preservative solution used. Research on erythro- 
cyte metabolism [7] has furthermore pointed to 
2,3-diphosphoglycerate (DPG) concentration as a 
key factor and one that should be measured as part 
of the control procedure. It is also necessary to 
measure red cell pH and P, and to check the 
efficiency of the NADNADH system which deter- 
mines the integrity of the methemoglobin-reduc- 
tase system and consequently of hemoglobin func- 
tion. 
Red cell flow characteristics can be assessed 
by chemical and by physical methods. As the main- 
stay of red cell deformability ATP must be mea- 
sured in any control procedure. Some investigators 
also recommend measurement of the red cell 
nucleotide concentration [JJ. K+ and Na+ should 
also be determined, as they reflect the efficiency 
of the different enzyme pathways involved, nota- 
bly the sodium pumps. 
Most of the physical tests are simple to per- 
form. One such test is light microscopic examina- 
tion of red cell shape and determination of the 
proportion of echinocytes. For complete quality 
control, scanning electron microscopic examination 
can give valuable information, including the sphe- 
rocyte count. Measurements of red cell osmotic 
resistance, filterability [2] and viscosity complete 
the checklist for control of flow properties. In 
addition, determination of the filtration pressure is 
useful in assessing the volume and number of ag- 
gregates in the unit, although this test is not uni- 
versally believed to reflect the properties of trans- 
fused blood in vivo [4]. 
Quantitative Tests 
The second set of tests required for good quali- 
ty control concerns the quantity of hemoglobin 
transfused. Once conditions for good red cell oxy- 
gen-releasing capacity and flow characteristics are 
met, the effectiveness of transfusion will depend 
on the number of hemoglobin molecules injected. 
This number can be calculed from the red cell 
count and the measurement of hemoglobin content, 
from the weight of the blood unit and from the 
respective volumes of blood components (residual 
plasma and erythrocytes). 
Transfusion Hazards 
The third set of tests concerns transfusion risks, 
first and foremost the immunologic risk, although 
with routine crossmatching this hazard has been 
greatly reduced. ABO grouping and Rh or Kell 
typing and the search for irregular antibodies in 
whole blood have become standard transfusion 
screening practice. The risks of bacterial, viral or 
parasitic contamination are much greater and 
therefore make far more imperative demands on 
quality control. Culturing in suitable media pro- 
vides adequate bacteriologic screening, although the 
risk of bacterial contamination has been greatly 
reduced with the advent of sealed plastic transfer 
systems. Testing for HBeAg and HBc antibody 
should be mandatory, as is testing for HBsAg, since 
post-transfusion viral hepatitis is currently a major 
transfusion hazard. Screening for plasmodia by im- 
munofluorescence techniques is advisable. Other 
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less vital quality control tests include measurement 
of plasma ammonium and hemoglobin. 
In preparing specific red cell units, as men- 
tioned above, certain tests should be added to the 
above list (although the short interval between 
preparation and injection of washed erythrocytes 
makes bacteriologic testing difficult), namely, de- 
termination of WBC and residual platelet counts 
(for leukocyte-poor, platelet-poor and washed 
packed cell preparations) and of glycerol content 
in frozen red cells. 
Conclusions 
Current blood banking in France includes com- 
pulsory immunologic and viral screening tests, in 
addition to the control procedures recommended 
above. All these tests, however, cannot be performed 
on every blood unit to be transfused. A sampling 
procedure is necessary to determine which and 
how many units have to be tested. However, each 
and every unit should be checked at least for 
weight, relative volumes of components, and Hb 
concentration and content. 
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H. H. Gunson. The source material for red cell 
products is the donation of whole blood. Consid- 
eration of quality control procedures, therefore, 
must begin with the donor. Detailed medical ex- 
amination of donors is not always practical before 
blood donation and one is often dependent upon 
the donor for history of past o r  current illness 
which may exert undesirable effects on the recipi- 
ent of the blood. Various tests can be applied to  
the donation, e.g., syphilis, hepatitis Bs antigen, 
and in many countries these are routine. The sensi- 
tivity of the tests, e.g., for HBsAg may vary, how- 
ever, and uniformity of testing using the most 
sensitive test available would be an advantage. 
Other tests applied to the blood donation may 
vary from centre to centre, e.g., cytomegalus anti- 
body tests, provision of 0 Rh-negative blood which 
is Kell-negative and contains a low titre of anti-A 
and anti-B. The provision of blood characterised 
by such tests often depends on local transfusion 
practice - standardisation can only be achieved by 
wide acceptance of the procedure as significantly 
beneficial to the patient. 
One test widely practised prior to donation is 
the estimation of haemoglobin concentration of the 
donor. In Great Britain and certain other countries, 
male donors are rejected if the haemoglobin con- 
centration is below 13.5g/dl, and femal donors if 
the concentration is below 12.5g/dl. Thus, a vari- 
able haemoglobin concentration and packed cell 
volume will inevitably occur in the whole blood 
donations. Furthermore, the common practice of 
removing a given volume of plasma from whole 
blood donations to prepare red cell concentrates per- 
petuates the variability in that product. Thus, in 
the British Pharmacopoeia, concentrated red cells 
are defined as the preparation resulting from re- 
moval of not less than 40% of the plasma (and 
anticoagulant) from a unit of whole blood. This 
definition can embrace a wide range of red cell 
concentrates and perhaps, with advantage, this 
product should be defined in terms of the packed 
cell volume of the preparation. 
Whole blood contains many cellular elements 
and plasma factors other than red cells and each 
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may be subject to biological variation. Other fac- 
tors which may introduce variables include the 
care taken and ease of venepuncture, the length 
of time for the donation and the period elapsing 
before the donation is cooled to 4 OC. Such factors, 
however, probably affect the viability of red cells 
less than other more labile constituents; thus, a pe- 
riod of 6 h at ambicnt temperature prior to refrig- 
eration of blood at 4 OC had little adverse effect 
on post-transfusion survival of red cells [l]. How- 
ever, it must be remembered that there are differ- 
ences between donors in the post-transfusion red 
cell survival [2]; a factor which cannot be sub- 
jected to standardisation. 
Various anticoagulant/preservative solutions 
are used for red cell preparations, commonly acid 
citrate dextrose (ACD) or citrate phosphate dex- 
trose (CPD) with or without the addition of ade- 
nine. The proportion of blood to anticogulant is 
an important factor affecting survival of the red 
cells and careful monitoring of the filling of con- 
tainers is essential. Biochemical changes occur as a 
result of red cell storage in vitro and the rate 
change varies with the anticoagulant used. Thus 
2,3-DPG levels fall more rapidly in blood stored 
in ACD compared with that in CPD: ATP levels 
also fall but are maintained at a higher concentra- 
tion when adenine is added. Whilst ATP is one 
factor which plays a part in red cell viability, 2,3- 
DPG and ATP influence the oxygen-transport 
function of the red cell. The significance of main- 
taining adequate levels of 2,3-DPG in transfusion 
practice has been the subject of considerable de- 
bate and it may have importance in transfusions in 
certain clinical situations [3]. It has been suggested 
that the use of preserved red cells with elevated 
levels of 2,3-DPG and ATP, prepared by incubat- 
ing with solutions containing adenine, pyruvate, 
inosine, glucose and phosphatees followed by saline 
washing are functionally superior to blood stored 
under normal conditions [4]. 
Additional treatment of processing of red cell 
preparations such as that cited above or following 
the reconstitution of frozen cells requires adequate 
quality control. When several solutions come into 
contact with the red cells in association with cryo- 
preservation or other treatment, documentation of 
all reagents should be meticulously carried out. 
The acceptability of the processed red cells for 
transfusion should be evaluated and various tests 
have been recommended for frozen-thawed red 
cells [5] which depend on the use of osmolality 
determinations of the final supernatant compared 
to normal serum or the degree of free haemoglobin, 
with a definition of acceptable limits. 
All procedures involving ‘open’ systems will 
lead to the increased risk of bacterial contamina- 
tion. It is not practical to perform cultures on 
such preparations prior to transfusion and reduc- 
tion of storage time to 24 h after processing is 
usual. This applies particularly to frozen-thawed 
red cells and leucocyte-poor blood. The latter prep- 
aration is usually administered to patients suffering 
febrile reactions due to leucoagglutinins and may 
be prepared by filtration through scrubbed nylon 
or cotton wool filters or by saline washing proce- 
dures with or without prior sedimentation with 
rouleaux-inducing agents such as dextran or hy- 
droxyethyl starch. Frozen-thawed red cells are al- 
so leukocyte poor. It is not surprising that uni- 
formity of the product is difficult to achieve when 
it is prepared in so many ways. It must be borne 
in mind that the purpose of the leucocyte-poor is 
to transfuse the patient with red cells containing 
few leucocytes; it was shown by Dausset et al. [6] 
and has been confirmed by others that removal 
of at least 90% of the leucocytes in a unit of blood 
may be necessary to prevent febrile reactions due 
to leucoagglutinins. With the availability of auto- 
mated cell counters measurement to ensure that 
this criterion is fulfilled could be carried out prior 
to transfusion. 
In conclusion, there is a biological variation 
associated with red cell preparation which is diffi- 
cult, and in some instances impossible, to quality 
control to effect a standard product. However, 
with the use of increasingly complex procedures 
and with products for specific functions, quality 
control is feasible and it is important that it be 
carried out both from the point of view of the 
safety of the transfusion and the predictability of 
the clinical effect of the transfused product. 
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William Y. Miller. Red blood cell transfusions 
are given for the purpose of increasing oxygen 
delivery to tissues. Red blood cell concentrates 
are, in the majority of circumstances, the best 
product performing this function but special pa- 
tient needs - such as expansion of the blood vol- 
ume (or, conversely, the prevention of circulatory 
overload) or transfusion with unwanted cellular 
and plasma constituents - often require selection 
of other transfusion products. In any case, the 
transfusionist has certain expectations which must 
be met: (1) the dose size must be consistent in order 
to provide predictable increments in the erythro- 
cyte mass; (2) erythrocyte survival should be as 
nearly normal as possible so that the frequency 
of transfusions can be predicted, and (3) the eryth- 
rocytes should function normally so that their 
expected benefits to tissue oxygenation can be 
achieved. 
Furthermore, the transfusionist expects that it 
should be possible to minimize adverse effects. It 
may be necessary to alter the plasma volume of 
the red cell concentrate to meet the patient’s phys- 
iologic state; that is, the hypovolemic patient may 
require that the plasma be retained, or the patient 
with cardiac or renal disease may require that 
plasma volume be further reduced. 
Finally, it may be necessary to  reduce the con- 
centration of other cellular constituents to prevent 
febrile non-hemolytic transfusion reactions or allo- 
immunization. 
The quality control procedures used to assure 
consistency of the final product must be sufficient- 
ly comprehensive to meet all these needs but not 
sufficiently complicated so as to unduly compli- 
cate or add unnecessarily to the cost of transfusion. 
The total volume of the product should be clearly 
displayed on the label, accurate to plus or minus 
10%. This is, of course, best done by accurately 
weighing the product at the time of collection and 
separation. Since the hematocrit of the final prod- 
uct is important, not only to the calculation of 
the dose but to the function and survival of the 
red cells at the end of the period of storage - es- 
pecially in CPDA-1 - measurement of the final 
hematocrit and its retention in a fairly narrow 
range is desirable for all red cell components as 
well. Assuming careful donor selection and reason- 
able attention in the component preparation lab- 
oratory, it should not be necessary to measure 
each dose prepared but only enough units to as- 
sure consistency. For those components in which 
cellular reduction is essential (leukocyte-poor red 
blood cells, for example), standards of reduction 
must be agreed upon, and a sufficient number of 
units measured to assure that the desired cellular 
reduction has been consistently achieved. 
The best indicator of erythrocyte survival is the 
degree of maintenance of adenosinetriphosphate 
(ATP) levels and the best available predictor of 
oxygen delivery function is the maintenance of 2,3- 
diphosoglycerate (2,3-DPG) levels. Existing anti- 
coagulant preservative solutions are so formulated 
as to provide acceptable maintenance of these es- 
sential nutrients so that it is not necessary to mea- 
sure them in the processing laboratory. Products 
prepared so as to assure accurate and consistent 
final volumes and hematocrits and prepared by 
published and recommended proccesses should as- 
sure maintenance of both ATP and 2,3-DPG. 
In summary, the quality control of erythro- 
cytes components should concentrate on measure- 
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ment of the initial volume, the final volume, and 
the hematocrit so as to assure consistent dosage 
size, appropriate red cell survival, and necessary 
red cell function. The label of the final product 
must indicate the final volume and hematocrit ac- 
curate to at least plus or minus 10%. In those 
products in which a cellular component or plasma 
is removed for special transfusion requirements, 
the label should clearly indicate the technique and 
degree of such removal. Routine use of sophisti- 
cated biochemical measurements and routine mea- 
surement of volume and hematocrit on each trans- 
fusion product is unproductive and unwarranted. 
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Byron A .  Myhre. Blood banks must routinely 
perform some quality control procedures on all 
blood components and derivatives to contribute to 
the safety and therapeutic effectiveness of the final 
product. However, the amount and type of quality 
control depends greatly on the product being 
prepared. Plasma derivatives, i.e., chemical frac- 
tions, begin as a pool of plasma made from a num- 
ber of donoors and represent a large volume (of- 
ten 1,000 liters or more). Therefore, it is relatively 
easy to draw off aliquots during the fractionation 
process and analyze them. Further, after fractiona- 
tion most of the derviatives are heat treated and 
filtered, thereby decreasing the possibility of con- 
tamination. On the other hand, red blood cell com- 
ponents (and other formed elements as well) can- 
not be pooled or heat treated and therefore must 
be treated as individual lots. Performing analyses 
on these components requires either a noninvasive 
method or else the sacrifice of the unit. For this 
reason, most quality control procedures for red 
cells should be limited in number, and must be 
carried out by a statistical sampling of individual 
components rather than a serial sampling of each 
batch in production. 
General 
A differentiation should be made between 
quality assurance procedures which are nice to 
know, those which are easy to perform, and those 
that provide patient safety. They are not necessarily 
similar [l]. 
Quality assurance procedures should be signifi- 
cant and effective. Meaningless quality assurance 
is a waste of time and money. Enough units should 
be studied to assure the effectiveness and safety 
of the components, and yet not waste a number 
of units which could be transfused. The number of 
units tested should be proportional to the number 
processed and not limited to any arbitrary number. 
Much of the safety of red cell components be- 
gins with the use of adequate criteria to screen 
and process donors and the use of donors who 
will not lie. Usually, this means volunteer donors. 
The donor should not have a history of hepatitis 
nor any other disease which could be transmitted 
through the blood itself. 
At the time of donation, the venepuncture site 
should be prepared in such a way that the maxi- 
mum number of skin organisms are removed. Un- 
der no circumstances should the prepared site be 
subsequently touched with the finger. Finally, the 
donor tubing should be tightly sealed and the blood 
unit promptly refrigerated if it is not to be used 
as a source of platelets. All of these precautions 
will prevent the unit from being contaminated. 
Previous studies must have been carried out to 
assure that the anticoagulant is stable and sterile, 
and that the plastic has been studied so that the 
bag system has been shown to be capable of pre- 
serving a normal unit of blood for its acceptable 
storage time with minimal hemolysis. These studies 
have been performed at the time the bag was ac- 
cepted for use. 
Quality assurance procedures need to be tailored 
to the eventual use of the product. For  example, 
the amount of plasma in a unit of red cell concen- 
trate may be perfectly acceptable to the average 
patient, yet may cause a serious reaction in a pa- 
tient with anti-IGA. On the other hand, it would 
be silly to require all units of red cell concentrates 
to have very low levels of plasma so that it would 
be acceptable for this specific patient. 
Let us now consider the individual red cell 
components. 
Red Cell Concentrate 
This component is used primarily when a pa- 
tient needs a maximal number of red cells in a 
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minimal volume. The most important measure- 
ments are therefore total volume (weight) and total 
red cell mass (hematocrit). These should be checked 
periodically on random units to show that the re- 
sulting product is adequate. Occasionally, there is 
need for units with low levels of electrolytes or 
other plasma-soluble metabolites. These should be 
prepared just prior to transfusion and should be 
assayed at that time. Periodic observations should 
be made on all red cell concentrates which are 
stored to show that there is only a small amount 
of red cell autolysis at that specific hematocrit. 
Washed Red Cells 
Usually, these cells are washed to remove pro- 
tein (for use in a patient with anti-IgA) or to re- 
move leukocytes (for a patient with symptomatic 
leukoagglutinins). As with all red cell units, it is 
necessary to determine periodically the number of 
red cells present to make certain that not too 
many of them have been lost during washing. Fur- 
ther, washing usually requires that the blood unit 
be entered, so sterility testing must be done if the 
washed cells are to be stored for more than 3-6 h. 
We have found that this testing can be done easily 
with a radioisotopic method [2] which gives a re- 
liable answer quickly. Sterility testing need not be 
done if the washing solutions are known to be 
sterile, and if the cells are to be transfused imme- 
diately. Protein determinations and/or leukocyte 
counts should be done periodically to assure that 
these components have been decreased. There are 
no universally accepted guidelines as to how much 
of these components should be removed to prevent 
clinical reactions. Therefore, it probably is best to 
remove as much as possible, and keep records for 
future studies. 
Leukocyte-Poor Red Cell Concentrates 
Periodic hematocrit determinations and leuko- 
cyte counts should be made on these units, but 
they need not be studied for sterility unless the unit 
has been entered. 
Frozen Red Cells 
Most of the studies previously listed should be 
performed on this component, but in addition, the 
glycerin content should be determined occasion- 
ally. There is a certain amount of controversy as to 
how much of this constituent is acceptable, but the 
best approach is to keep it as low as possible. Al- 
though a method to determine glycerin chemically 
has been described [3], it does not always give 
consistent results. Huggins [4] has championed a 
‘simulated transfusion’ in which the cells are in- 
cubated with saline. Roberts [5] has proposed the 
determination of osmolarity but it requires expen- 
sive equipment and some time. The simplest, which 
was suggested to us [6] is to determine the total 
solids contents of the supernatant with an optical 
total solids meter. 
Although the use of adequate quality control 
procedures will contribute to a more safe and ef- 
fective blood unit, there is one extremely impor- 
tant point to remember. The blood components 
were being given to treat a patient with a specific 
problem. Certainly, the ultimate quality assurance 
procedure is an evaluation of the patient’s response 
to the transfusion, and the presence or absence of 
side effects. Pre- and post-transfusion hemoglobin 
measurements always should be made; and in 
those transfusions in which there is an adverse re- 
action, studies should be carried out to determine 
its cause, and if it was due to poor preparation of 
the component. Therefore, a well-functioning re- 
porting system between the blood center and the 
surrounding hospitals is an absolute requirement 
and represents the final step in quality assurance 
of any blood component or derivative. 
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Harold A. Oberman. The singular clinical ob- 
jective of transfusion of red cells is the augmenta- 
tion of the patient’s capacity for tissue oxygena- 
tion. Therefore, the accomplishment of this goal 
depends upon the number of red cells which sur- 
vive in the patient following transfusion and their 
functional integrity. 
The number of functionally active red cells 
which survive after transfusion varies with the vol- 
ume of blood originally collected, the manner of 
collection, the hematocrit of the blood donor, the 
duration and manner of storage of the unit of 
blood, the serologic compatibility of the unit of 
the donor red cells with the patient’s serum, the 
manner of transfusion of the unit of blood, and, if 
red cell components are being administered, the 
manner of preparation of these components. 
The Standards of the American Association of 
Blood Banks 111 sets forth minimum requirements 
of safety and efficacy for the red cell-containing 
products specified in the question. However, I do 
not believe that it is practical, or necessary, to 
standardize the indicated products with respect to 
potency, in a manner analogous to plasma deriva- 
tives. As indicated above, there are far too many 
variables involved, and it would prove cumber- 
some for each Blood Bank to  monitor each unit 
of blood daily, with corresponding modification 
of the label, to indicate the number of red cells 
predictably available for the patient in each unit 
of blood. 
It is self-evident that one may transfuse units 
of blood which meet acceptable requirements with 
respect to volume of blood collected, minium do- 
nor hematocrit or hemoglobin level and minimally 
acceptable conditions and duration of storage, yet 
there may be wide variation in the number of 
functionally active red cells received by the patient 
from different units. For  example, let us assume 
that donor A, with a hematocrit of 46%, donates 
490ml of whole blood, while donor B, with a 
hematocrit of 41%, donates 410ml of whole blood. 
Let us also assume that the unit of blood from 
donor A is transfused during the 5 day of storage, 
while that of donor B is transfused during the 20th 
day of storage. The difference in the number of 
red cells which would survive in the recipient 24 h 
after transfusion of these units, all other factors 
being equal, may approach 90 ml! 
Such wide variation in the functional capacity 
of individual units of red cell-containing products 
is permissible only because of the inexactitude of 
blood transfusion therapy in the adult patient. In 
contrast, it is often necessary to be considerably 
more specific in the management of the neonate. 
In this situation use of blood less than 5 days old, 
as well as of devices for exact measurement of 
volume of blood product transfused, permits some- 
what greater control of the number of red cells 
administered. 
Although it is impractical for the blood bank 
to monitor each unit of blood daily so as to indi- 
cate the number of red cells which will predictably 
survive in the recipient of each unit, the laboratory 
must ensure more manageable factors which opti- 
mize the survival of the transfused red cells. For 
example, acceptable conditions of storage of the 
unit of blood must be stringently enforced, and 
testing for evidence of serological incompatibility, 
including donor and patient typing, must be pre- 
cise. In addition, the transfusion should be con- 
ducted in such a manner as to assure the survival 
of the transfused red cells, as by avoiding excessive 
warming of the unit of blood and preventing con- 
tact of the blood with incompatible intravenous 
solutions. 
Not only must there be standardization of those 
factors which relate to the survival of the red cells, 
but also there must be minimum standards pre- 
pared related to the safety of the product. For ex- 
ample, the risk of transmission of disease through 
the transfusion must be mitigated, and asepsis must 
be maintained during both the collection and stor- 
age of the unit of blood. Finally, human error 
must be avoided in all phases of the collection, 
storage, processing and transfusion procedure. 
Although it may seem inconsistent to specify 
the minimum cellular content of platelet concen- 

238 International Forum 
that human exposures to SIC could be justified for 
this purpose in the absence of significant evidence 
of a problem with quality of red cell products. 
The same can be said about culturing bloods 
for contamination with microorganisms. A unit 
found to be significantly contaminated is such a 
rare event that a large number of cultures would 
be required to establish a valid measure of the 
rate of contamination. Careful inspection of blood 
units prior to administration seems preferable, with 
recognition that not all significantly contamined 
units will be detected by this approach. It might 
be wise to require culture examination of at least 
all suspected units with full identification of any 
isolated organisms as a basis for further epidemio- 
logical investigation of the source and mechanism 
of contamination. 
At present, QC of red cell products for hepa- 
titis infectivity is based primarily on the use of 
‘state of the art’ third generation hepatitis B sur- 
face antigen tests. There seems to be little added 
benefit from testing for hepatitis B antibodies. Hep- 
atitis surveillance among recipients with exclusion 
of implicated donors by use of a registration pro- 
cess and electronic data processing equipment is at 
present the only technique available for elimina- 
tion of carriers of non-A, non-B hepatitis from the 
donor pool, in the absence of a useful serological 
test for these agents. The need for such a test is 
self-evident. 
Although not strictly a part of product QC, 
the chain of procedures from patient and donor 
identification, and determination of ABO and Rho 
groups, through the cross-match or ‘type and 
screen’ procedure to the actual administration of a 
unit of red blood cells, provides a major opportu- 
nity for enhancement of recipient safety. Clerical 
errors continue to plague the practice of transfusion 
at this level. Here automation and data processing 
technology may be the way of the future. The 
cost of this approach must be justified primarily 
on the grounds of safety. At present, equipment 
does not exist which will carry this chain of data 
to the recipient’s bedside. And when it does arrive, 
it will require a significant experience to be sure 
this system is truly ‘bug free’. 
Opinion in the US does not support routine 
extended blood typing of donor and recipient for 
additional red cell antigens such as the other prin- 
cipal antigens of the Rh or Kell systems. Granted, 
some alloimmunizations could be avoided, but 
these are rarely a serious problem. The cost of ex- 
tended typing is considerable and the logistic prob- 
lem is substantially increased for little return in 
safety. 
Of course, all new blood preservation processes 
or significant changes in established methods 
should continue to be subjected to evaluation by 
in vivo studies of red cell survival. Improved meth- 
ods of surveillance of experience with new and old 
red cell products in the field where they are being 
used will provide another probably useful approach 
to QC of these materials. 
These and related questions have been con- 
sidered in depth over the last 3 years by Panel 6 
of the Bureau of Biologics, Food and Durg Ad- 
ministration, on Safety and Efficacy of Blood and 
Blood Derivatives of which the author served as 
Chairman. The report of this panel will be pub- 
lished in the Federal Register. While not presum- 
ing to speak for the Panel officially, the opinions 
expressed above are in general agreement with 
positions taken by the Panel [4]. 
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Thomas F. Zuck. The question asked is whether 
or not the same principles applied to the quality 
control of plasma derivatives should be applied to 
the quality control of cellular blood components. 
Developing parameters for cellular products poses 
three difficulties not encountered in similar en- 
deavors for plasma derivatives. First, cellular com- 
ponents are almost invariably administered as in- 
dividual units from single donors, whereas plasma 
derivatives are manufactured from large multido- 
nor pools. Unavoidable interdonor biological vari- 
ations are leveled by subdividing large plasma 
pools into individual dosages. This leveling is not 
possible to achieve with either red cell or cyt- 
apheresis products, and only partially possible to 
achieve through pooling of individual donor units 
of platelets. Further, the pooling of plasma for 
derivative manufacture permits a lot assay value 
to be assigned to multiple individual dosage units, 
whereas each donor unit of red cells or cytapher- 
esis cell would have to be assayed to achieve the 
same precision achievable with plasma pools. 
Second, cellular components require a suspend- 
ing medium to facilitate infusion. Some characteris- 
tics of these media, such as supernatant potassium 
concentration, may be as clinically relevant as the 
cellular parameters. Some, such as hemoglobin 
concentration, may reflect the tolerance of the 
cells to storage, but are extremely difficult or im- 
possible to control. Other media characteristics, 
such as the osmolality of the supernatant of thawed 
deglycerolized red cells are more practical, and 
their value more amenable to control. 
Table I indicates some measurements which 
might be contemplated to  standardize red cell prod- 
ucts, and indicates this writer’s opinion of their 
usefulness and practicality. The assumption has 
been made that all units would have to be assayed 
shortly prior to infusion, and that all blood banks 
could perform the assays reliably. The latter as- 
sumption is probably overly optimistic. Similar 
tables could be constructed for all cellular com- 
ponents. Thus, it may not be practical to offer 
Table I. Red cell parameters 
Parameter Useful Practical’ 
CelIular 
ATP contentration partially no 
2,3-DPG u n c 1 ear no 
In vivo survival Yes no 
P50 unclear no 
Deformability perhaps no 
Suspending medium 
Residual WBC selected cases perhaps 
Hemoglobin concentration selected cases perhaps 
Potassium selected cases perhaps 
Sodium selected cases perhaps 
Ammonia selected cases perhaps 
Osmolality (thawed cells) yes no 
Screen filteration pressure perhaps no 
Microaggregate volume perhaps yes 
Assumes that parameter is to be measured on 
each individual cell unit and that a sterile entry 
were possible so the dating period would not 
change. 
cellular components to the medical profession as 
‘standardized’ in other than the broadest sense of 
knowing the arithmetic mean values and standard 
deviations of an adequately studied number of sim- 
ilar products. 
Third, whereas in vitro assays of properly ad- 
ministered plasma derivatives tend to correlate 
rather well with in vivo performance, the corre- 
lation between in vitro markers used to product 
cellular viability and in vivo performance is much 
less precise. This difficulty was illustrated recently 
by the poor correlation between red cell ATP 
concentration and the in vivo survivability of red 
cells stored as concentrates in CPD-A1 [l]. 
It seems that the sheer number of procedures 
which would be required to ‘standardize’ individual 
units of cellular components would make this ef- 
fort extremely difficult. Any selection of para- 
meters for study should be made with care, with 
an eye focused on the cost-benefit ratio. Perhaps 
greater emphasis and resources placed in the area 
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of postinfusion patient monitoring for the clinical 
and laboratory effects of cellular components fol- 
lowing administration would be of greater benefit 
in improving hemotherapy practice. 
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Announcement 
The Blood Bank Director’s Training Program 
The New York Blood Center offers a post- 
doctoral training program for qualified physicians 
interested in a career in blood transfusion services. 
It is anticipated that persons completing the pro- 
gram will serve as full-time directors or associate 
directors of regional blood programs or hospital 
blood banks, research scientists, medical school 
faculty members or members of governmental regu- 
latory or advisory agencies. 
In the initial year, the training Fellow receives 
instruction in immunohematology, tissue typing, 
cryobiology, and protein chemistry in the various 
laboratories of the Center’s Lindsley F. Kimball Re- 
search Institute. Experience in regional blood pro- 
gram management is gained through active parti- 
cipation in the Greater New York Blood Program. 
In addition, each Fellow is assigned to one of 
several participating, university-affiliated hospital 
blood banks in New York City for training in 
clinical blood transfusion therapy and blood bank 
technology. A second year can be arranged to suit 
individual requirements for more intensive training 
in one or more areas. 
The program is accredited by the Liaison Com- 
mittee on Graduate Medical Education of the 
American Medical Association; the entire year is 
acceptable towards meeting eligibility requirements 
for the sub-specialty examination in blood banking 
of the American Board of Pathology. In addition, 
it is accredited by the Department of Education 
of the State of New York (for continuing edu- 
cation) and the Veterans Administration (for re- 
imbursement under the G.I. Bill of Rights). Re- 
quirements: (1) An MD degree with a minimum 
of 2 years’ post-doctoral training in clinical medi- 
cine or pathology; (2) Qualifications for obtaining 
a license to practice medicine in New York State 
by the beginning of the fellowship year; (3) US 
citizenship or permanent residency. Applications 
for the program beginning July 1, 1981 must be 
received before February 1, 1981. 
Further information may be obtained from 
Helen L. Keers, Administrative Assistant, Educa- 
tional Programs, The New York Blood Center, 
310 East 67th Street, New York, NY 10021 (USA). 
